Canakinumab for gout attacks. Too risky. -

Canakinumab for gout attacks. Too risky.

Abstract	There are no clinical trials of canakinumab in patients with gout attacks refractory to several prior treatments. Adverse effects mainly include infections, hypersensitivity reactions and dizziness.
Authors
Journal	Prescrire international (Prescrire Int) Vol. 23 Issue 151 Pg. 178 (Jul 2014) ISSN: 1167-7422 [Print] France
PMID	25162089 (Publication Type: Journal Article)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Interleukin-1beta canakinumab
Topics	Antibodies, Monoclonal (adverse effects) Antibodies, Monoclonal, Humanized Drug Hypersensitivity (etiology) Gout (drug therapy) Humans Interleukin-1beta (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!